Capricor Therapeutics Stock In The News

CAPR Stock  USD 7.67  0.01  0.13%   
Our overall analysis of Capricor Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Capricor Therapeutics. The specific impact of Capricor Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Capricor Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher. Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Capricor Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Capricor Therapeutics Backtesting and Capricor Therapeutics Hype Analysis.
To learn how to invest in Capricor Stock, please use our How to Invest in Capricor Therapeutics guide.

Capricor Therapeutics Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13
https://www.globenewswire.com/news-release/2025/08/06/3128365/0/en/Capricor-Therapeutics-to-Present-Second-Quarter-2025-Financial-Results-and-Recent-Corporate-Update-on-August-13.html
 Bullish
Macroaxis News: globenewswire.com
Bragar Eagel & Squire, P.C. Urges Invest...
https://www.globenewswire.com/news-release/2025/08/05/3127984/0/en/Bragar-Eagel-Squire-P-C-Urges-Investors-in-XPLR-Infrastructure-Centene-Biohaven-or-Capricor-to-Inquire-About-Their-Rights-in-Class-Action-Lawsuits.html
 Neutral
Macroaxis News: globenewswire.com
Levi & Korsinsky Reminds Capricor Therap...
https://www.globenewswire.com/news-release/2025/08/05/3127890/3080/en/Levi-Korsinsky-Reminds-Capricor-Therapeutics-Inc-Investors-of-the-Pending-Class-Action-Lawsuit-with-a-Lead-Plaintiff-Deadline-of-September-15-2025-CAPR.html
 Neutral
Macroaxis News: globenewswire.com
Investors in Capricor Therapeutics, Inc. Should Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights – CAPR
https://www.globenewswire.com/news-release/2025/08/04/3126938/0/en/Investors-in-Capricor-Therapeutics-Inc-Should-Contact-The-Gross-Law-Firm-Before-September-15-2025-to-Discuss-Your-Rights-CAPR.html
 Neutral
Yahoo News
Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory
https://finance.yahoo.com/news/ultragenyx-pharmaceutical-inc-rare-bull-193201521.html
 Bullish
Macroaxis News: globenewswire.com
ROSEN, A LEADING NATIONAL FIRM, Encourag...
https://www.globenewswire.com/news-release/2025/08/03/3126259/673/en/ROSEN-A-LEADING-NATIONAL-FIRM-Encourages-Capricor-Therapeutics-Inc-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-CAPR.html
 Bullish
Macroaxis News: globenewswire.com
Bragar Eagel & Squire, P.C. Urges Invest...
https://www.globenewswire.com/news-release/2025/08/02/3126194/0/en/Bragar-Eagel-Squire-P-C-Urges-Investors-in-XPLR-Infrastructure-Centene-Biohaven-or-Capricor-to-Inquire-About-Their-Rights-in-Class-Action-Lawsuits.html
 Neutral
Macroaxis News: globenewswire.com
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics
https://www.globenewswire.com/news-release/2025/08/01/3125947/683/en/SHAREHOLDER-REMINDER-Faruqi-Faruqi-LLP-Investigates-Claims-on-Behalf-of-Investors-of-Capricor-Therapeutics.html
 Neutral
Macroaxis News: globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
https://www.globenewswire.com/news-release/2025/08/01/3125872/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-Capricor-Therapeutics-Inc-CAPR.html
 Neutral
Macroaxis News: globenewswire.com
ROSEN, TOP RANKED GLOBAL COUNSEL, Encour...
https://www.globenewswire.com/news-release/2025/07/31/3125542/673/en/ROSEN-TOP-RANKED-GLOBAL-COUNSEL-Encourages-Capricor-Therapeutics-Inc-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-CAPR.html
 Bullish

Capricor Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Capricor and other traded companies coverage with news coverage. We help investors stay connected with Capricor headlines for the 7th of August to make an informed investment decision based on correlating the impacts of news items on Capricor Stock performance. Please note that trading solely based on the Capricor Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Capricor Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Capricor Therapeutics investors visualize upcoming and past events in order to time the market based on Capricor Therapeutics noise-free hype analysis.

Capricor Therapeutics Investors Sentiment

The influence of Capricor Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Capricor. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Capricor Therapeutics' public news can be used to forecast risks associated with an investment in Capricor. The trend in average sentiment can be used to explain how an investor holding Capricor can time the market purely based on public headlines and social activities around Capricor Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Capricor Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Capricor Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Capricor Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Capricor Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Capricor Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Capricor Therapeutics' short interest history, or implied volatility extrapolated from Capricor Therapeutics options trading.

Additional Tools for Capricor Stock Analysis

When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.